Insights

  • Date

  • Content Type

  • Reset

Article

Challenge accepted: Teams seeking a quantum shift for new antiviral agents through Germany’s federal agency SPRIN-D

20.09.22

By Dr. Maximilian Strunz

In 2021, the German Federal Agency for Disruptive Innovation, SPRIN-D, announced an antiviral challenge to

Article

SCIENTIFIC DUE DILIGENCE BUILDS BETTER BUSINESS RELATIONSHIPS

13.09.22

By Dr. Diane Seimetz & Jörg Schneider

The biopharma sector is seeing a proliferation of mergers, partnerships and acquisitions, but deals can

Article

Managing complex GMO requirements for gene therapy clinical trials

23.08.22

By Liron Sarid-Krebs

Regulators and industry organizations have raised concerns that Europe may be falling behind the United

Article

Europe’s complex reimbursement process puts access to ATMPs at risk

25.07.22

By By Emma Cheesman-Ungstrup and Alberto Rubio

A potential crisis with advanced therapy medicinal products (ATMPs) is looming in Europe. Concerns over

Article

Run like clockwork | Building successful partnerships with scientific due diligence

1.07.22

By Diane Seimetz & Joerg Schneider

For biotech companies and academic developers wishing to partner with larger firms is perhaps best…

Article

Bridging the perceived regulatory guideline gap for innovative medicines

21.06.22

By Jörg Schneider

There is a perception that regulatory guideline gaps across advanced therapeutic medicinal products (ATMPs) –